Home / Market News / $BIVI

$BIVI news and market catalysts

The 15 most recent market catalysts affecting $BIVI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 7 high impact 8 bullish 1 bearish Biotechnology
Nov 16, 2026 Corporate Catalyst Neutral Impact 65
BioVie Announces New Clinical and Biomarker Findings from Phase 2 ADDRESS-LC Trial of Bezisterim
BioVie announced new clinical and biomarker findings from its Phase 2 ADDRESS-LC trial of bezisterim for Long COVID. The key findings include the identification of two distinct bio…
Nov 7, 2026 Corporate Catalyst Bearish Impact 80
BioVie Reports 3Q 2026 Financial Results
BioVie Inc. reported a net loss of $0.68 per share for Q3 2026, primarily driven by increased R&D spending on its Long COVID Phase 2 program. This financial performance is generall…
Nov 4, 2026 Corporate Catalyst Neutral Impact 65
BioVie Announces $4.74 Million Registered Direct Offering and Concurrent Private Placement
BioVie Inc. announced a registered direct offering and concurrent private placement, raising approximately $4.74 million by selling 2,962,500 shares of common stock at $1.60 per sh…
Oct 26, 2026 Corporate Catalyst Neutral Impact 60
BioVie Invited to Present Data on Bezisterim at NIH's RECOVER-TLC Workshop
BioVie Inc. announced an invitation to present data on its drug, bezisterim, at the NIH's RECOVER-TLC workshop. This is significant because it provides a platform for BioVie to sho…
Oct 19, 2026 Corporate Catalyst Bullish Impact 85
BioVie shares are trading higher after the company announced the presentation of Phase 2 Long COVID data showing statistically significant improvements in fatigue and cognitive measures in certain patient subgroups treated with bezisterim.
This headline represents a major corporate catalyst for BioVie, as positive Phase 2 clinical trial data is a critical step in drug development, significantly de-risking the asset. …
Oct 19, 2026 Corporate Catalyst Neutral Impact 65
BioVie Reports Data From Phase 2 ADDRESS-LC Trial Of Bezisterim At 151st Annual Meeting Of American Neurological Association
BioVie Inc. announced the presentation of data from its Phase 2 ADDRESS-LC study evaluating bezisterim (NE3107) for Long COVID at a major neurological conference. This is a standar…
Oct 14, 2026 Corporate Catalyst Neutral Impact 75
BioVie To Present Phase 2 Bezisterim Data In Long COVID, Parkinson’s At Neurology Conference October 18-19
This headline represents a significant corporate catalyst for BioVie (BIVI). The presentation of Phase 2 clinical trial data for a drug targeting two major conditions, Long COVID a…
Sep 15, 2026 Corporate Catalyst Bullish Impact 85
What's Going On With BioVie Stock on Tuesday?
BioVie announced topline results from its Phase 2 ADDRESS-LC study for bezisterim in Long COVID patients. The primary issue driving the stock decline is that the full intent-to-tre…
Sep 15, 2026 Corporate Catalyst Bullish Impact 95
BioVie Announces Phase 2 ADDRESS-LC Trial Results Of Bezisterim In Long COVID
BioVie has announced positive topline results from its Phase 2 ADDRESS-LC trial for bezisterim, an investigational drug for Long COVID. The filing highlights statistically signific…
Sep 14, 2026 Corporate Catalyst Neutral Impact 85
BioVie Says Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID Did Not Achieve Statistical Significance On Any Endpoint In Overall Population, With Significant Results Only In Pre-Specified Subgroups; To Discuss Topline Results On September 15 Call
This headline represents a major negative catalyst for BioVie. The failure of bezisterim to achieve statistical significance in its Phase 2 Long COVID trial's overall population is…
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
BioVie shares are trading higher after the company announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
The completion of the last on-treatment visit for BioVie's Phase 2 trial is a significant de-risking event for the company. It signals that the trial has progressed as planned and …
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
BioVie Says Last On-Treatment Visit Completed In Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID; Expects Topline Results Before End Of September 2026
The completion of the last on-treatment visit in a Phase 2 trial is a critical milestone, indicating that the data collection phase is complete and analysis is underway. The expect…
Aug 13, 2026 Corporate Catalyst Bullish Impact 95
BioVie Q4 EPS $(0.70) Up From $(1.42) YoY
BioVie's Q4 earnings report shows a substantial reduction in per-share losses, moving from $(1.42) to $(0.70) year-over-year. This 50.7% improvement suggests better financial manag…
Aug 12, 2026 Market Technicals Bullish Impact 55
12 Health Care Stocks Moving In Wednesday's Intraday Session
This filing is a snapshot of intraday trading activity in the healthcare sector, specifically highlighting companies with notable price changes. The primary drivers for some of the…
Aug 6, 2026 Corporate Catalyst Bullish Impact 95
BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. Placebo
The successful Phase 2 trial for BioVie's bezisterim in early Parkinson's disease is a significant corporate catalyst. Meeting prespecified endpoints with statistically significant…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.